KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares OutstandingShares Repurchased
Ratios

Royalty Pharma (RPRX) Non-Current Receivables (2019 - 2025)

Historic Non-Current Receivables for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $15.8 billion.

  • Royalty Pharma's Non-Current Receivables rose 531.53% to $15.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 billion, marking a year-over-year increase of 531.53%. This contributed to the annual value of $15.1 billion for FY2024, which is 737.12% up from last year.
  • Per Royalty Pharma's latest filing, its Non-Current Receivables stood at $15.8 billion for Q3 2025, which was up 531.53% from $15.1 billion recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Non-Current Receivables registered a high of $15.8 billion during Q3 2025, and its lowest value of $12.6 billion during Q1 2021.
  • In the last 5 years, Royalty Pharma's Non-Current Receivables had a median value of $13.7 billion in 2021 and averaged $14.0 billion.
  • In the last 5 years, Royalty Pharma's Non-Current Receivables soared by 1749.34% in 2021 and then tumbled by 739.76% in 2023.
  • Over the past 5 years, Royalty Pharma's Non-Current Receivables (Quarter) stood at $13.7 billion in 2021, then dropped by 1.64% to $13.5 billion in 2022, then grew by 4.41% to $14.1 billion in 2023, then increased by 7.37% to $15.1 billion in 2024, then increased by 4.21% to $15.8 billion in 2025.
  • Its Non-Current Receivables was $15.8 billion in Q3 2025, compared to $15.1 billion in Q2 2025 and $15.0 billion in Q1 2025.